Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS

Lyra Therapeutics, Inc.

2023-Q3 EPS reported -$1.04 revenue$1,412,000

CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.
SNOT-22 improvement maintained at Week 28: -17.6 points (p=0.007) vs sham.
Cash, equivalents and investments $102.6M, sufficient into Q1 2025.
ENLIGHTEN I Phase 3 fully enrolled; topline results expected 1H 2024.
Net loss $15.7M vs $14.8M year-over-year; R&D spend up to $12.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyra Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.